{
  "id": "pharmacy",
  "title": "Pharmacy",
  "lang": "en",
  "source_lang": "en",
  "summary": "Pharmacy encompasses the sciences and professional practices concerned with developing, preparing, supplying, and ensuring the appropriate use of medicines.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [],
  "generated_at": "2026-10-13",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/pharmacy/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/pharmacy/",
      "json": "https://aiwiki.page/zh/pharmacy.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Pharmacy is the field concerned with medicines: their discovery and development, formulation and preparation, quality, supply, and use in patient care. It connects the pharmaceutical sciences with a health profession whose practitioners, pharmacists, help ensure that medicines are used safely and effectively. Its scientific foundations draw on chemistry, biology, and pharmacology, while its professional practice operates within health systems. The word also denotes premises where medicines are prepared or dispensed, although the field extends beyond those establishments. (pharmacy.wisc.edu)\n\nPharmacy links research on drug discovery, action, and delivery with the practical responsibilities of preparing and supplying medicines, managing medication therapy, and supporting public health. Its scope includes laboratory research, industrial production, community and hospital services, education, and medicines policy. These activities address interconnected questions of product quality, therapeutic effectiveness, patient safety, and access to essential medicines; professional responsibilities and legal authority differ among jurisdictions. (pharmacy.wisc.edu)"
    },
    {
      "heading": "Scope, Terminology, and Disciplinary Boundaries",
      "text": "Pharmacy denotes both a scientific field concerned with the preparation and use of medicines and a health profession concerned with their supply and appropriate use. In scientific contexts, the term encompasses knowledge about medicinal substances, formulations, and delivery; in professional contexts, it includes dispensing, assessing medicine-related problems, and communicating with patients and other health professionals. A pharmacy, by contrast, is an establishment or organizational unit where medicines are prepared or dispensed, such as a community outlet or hospital department. The establishment is not synonymous with the discipline, and pharmacists also work outside dispensing premises, including in research, industry, and clinical services. (bps.ac.uk)\n\nPharmaceutical sciences comprise an interdisciplinary research domain drawing on chemistry, biology, engineering, and related subjects. Medicinal chemistry investigates the design and properties of potential therapeutic compounds; pharmaceutics concerns their formulation and delivery as usable medicinal products; analytical and biological sciences contribute methods for examining composition, quality, activity, and toxicity. These are connected areas rather than alternative names for pharmacy practice. The University of Wisconsin–Madison, for example, organizes its pharmaceutical-sciences research into three cores—drug discovery, drug action, and drug delivery—encompassing medicinal chemistry, pharmaceutical biochemistry, pharmaceutics, biotechnology, pharmacology, and toxicology. Its research program accepts backgrounds in physical, biological, and engineering sciences as well as pharmacy, illustrating that pharmaceutical scientists need not be pharmacists. (pharmacy.wisc.edu)\n\nPharmacology specifically investigates how drugs act on living systems, including their therapeutic and harmful effects. It supplies knowledge used in both pharmaceutical research and clinical care, but is not interchangeable with pharmacy: studying a compound’s biological action differs from developing its dosage form or supplying it to a patient. Medicine addresses disease prevention, diagnosis, and treatment more broadly; medicines constitute one therapeutic means within that wider field. Clinical pharmacology connects research on drugs in humans with their therapeutic use, while pharmacy practice applies scientific and clinical knowledge to medicine supply, review, and patient care. These boundaries overlap in collaborative work rather than dividing knowledge into mutually exclusive territories. (bps.ac.uk)\n\nThe medicine life cycle begins with discovery and development, undertaken by researchers in universities, companies, and other institutions. Laboratory investigators examine candidate substances; clinical investigators and participants generate evidence about their effects in humans; sponsors coordinate development; and regulators assess the submitted evidence. Manufacturing adds a distinct requirement: a candidate must become a reproducible product with documented ingredients, processing, and packaging. The United States Food and Drug Administration describes five broad stages—discovery and development, preclinical research, clinical research, regulatory review, and post-market safety monitoring. This framework identifies different evidential tasks, not activities performed exclusively by pharmacists. (fda.gov)\n\nAfter production, medicines pass through procurement, storage, distribution, preparation where required, dispensing, administration, and monitoring. Pharmacists contribute product expertise and medication review; technicians support dispensing and inventory work; prescribers determine treatment within their authorized scope; and patients, carers, nurses, and other professionals participate in administration and observation of outcomes. The 2011 joint guidelines of the International Pharmaceutical Federation and the World Health Organization identify four broad pharmacist roles, including handling medicinal products, managing medication therapy, maintaining professional performance, and supporting health-system effectiveness. They also include disposal within product responsibilities: expired or unwanted medicines require arrangements distinct from dispensing, involving collection and destruction systems as well as pharmacy services. National rules determine the precise allocation of these responsibilities. (bls.gov)"
    },
    {
      "heading": "Historical Development",
      "text": "A Sumerian clay tablet from Nippur in Mesopotamia, catalogued by the Penn Museum as approximately 2200 BCE, preserves medicinal prescriptions: evidence that preparation knowledge was being recorded long before pharmacy became a distinct profession. Mesopotamian texts describe operations such as pulverizing, boiling, filtering, and combining ingredients. In ancient Egypt, the Ebers Papyrus, dating to approximately 1550 BCE, likewise records medicinal preparations. These documents establish the existence of organized therapeutic practices, not the clinical effectiveness of every remedy; practical procedures and religious or magical explanations could coexist within the same medical tradition. (pennmuseum.org)\n\nThe Greek physician Pedanius Dioscorides, working within the Roman Empire, wrote the five-book De materia medica around 50–70 CE. Its descriptions of medicinal substances, preparation, properties, and testing became an influential model for materia medica—the accumulated knowledge of materials used medicinally—in Europe and the Middle East. (mainweb.awsprod.nlm.nih.gov) In China, the Shennong bencao jing, compiled during the Han period and conventionally dated around the first century CE, was attributed to the legendary Shennong rather than demonstrably authored by him. It became a foundational text of Chinese medicinal traditions. In India, the layered Charaka Samhita, associated with the early centuries CE and subsequently revised, organized therapeutics within Ayurveda, including medicinal substances, diet, and theories of bodily balance. These classifications expressed their respective historical medical systems, rather than modern pharmacological categories. (en.wikipedia.org)\n\nDuring the Islamic Golden Age, Arabic translations made Dioscorides’ materia medica and Galen’s writings on simple remedies available to scholars who developed further pharmaceutical literature. Galen’s alphabetical arrangement of substances influenced Arabic reference works. Formularies served a different purpose: they recorded combinations of ingredients, often grouping preparations by type, such as salves, laxatives, or eye remedies; some were written specifically for hospitals. (mainweb.awsprod.nlm.nih.gov) Knowledge subsequently circulated into Latin-reading Europe through translation as well as trade. In twelfth-century Toledo, Gerard of Cremona translated both Arabic medical works and Arabic versions of Greek texts, including Avicenna’s Canon of Medicine. This transmission involved the adoption of newly composed syntheses, not simply the preservation of ancient books. (nlm.nih.gov)\n\nThe differentiation of prescribing from preparing and selling medicines proceeded unevenly. Frederick II’s pharmaceutical enactments of 1240 are a prominent medieval example of formal separation, but they did not establish a universal professional boundary. (pharmacists.ca) European apothecaries developed specialist compounding and dispensing skills while retaining different relationships with physicians and commercial guilds. London’s Society of Apothecaries received its royal charter on 6 December 1617, separating it from the Grocers’ Company. Yet its later authority to license medical practitioners, beginning in 1815, demonstrates that the English apothecary’s development did not follow a simple progression toward dispensing alone. (apothecaries.org)\n\nNineteenth-century institutionalization connected pharmacy more closely with laboratory chemistry, formal education, and published standards. The first United States Pharmacopeia, issued in 1820, sought greater uniformity in medicinal substances and preparations. Philadelphia apothecaries and wholesale druggists founded the Philadelphia College of Pharmacy in 1821, creating an organized educational institution alongside apprenticeship. (dev.usp.org) Production also began moving beyond the individual dispensary: Heinrich Emanuel Merck expanded his Darmstadt pharmacy into industrial-scale manufacture in 1827. Such enterprises linked chemical preparation with production for wider markets, although their emergence did not immediately eliminate local compounding. (sigmaaldrich.com)\n\nTwentieth-century developments combined large-scale drug production with new patient-oriented responsibilities. Penicillin illustrates the industrial transformation: submerged fermentation, improved recovery, and coordinated wartime production increased United States output from 21 billion units in 1943 to 1,663 billion in 1944. (acs.org) A later American practice example was the University of California, San Francisco’s experimental ward pharmacy, opened at Moffitt Hospital on 7 September 1966. Pharmacists combined medicine distribution with admission medication histories, patient-specific records, discharge instruction, and information services for clinical staff. The project provided a concrete setting for developing clinical pharmacy and revising professional education around direct participation in patient care. (pharmacy.ucsf.edu)"
    },
    {
      "heading": "Medicinal Chemistry, Pharmacognosy, and Drug Discovery",
      "text": "Medicinal chemistry combines organic chemistry, structural biology, and pharmacology to discover and improve molecules with potentially useful biological activity. Target-based discovery begins by identifying a molecular component—such as an enzyme, receptor, or other protein—whose modification might alter a disease process. Target validation tests that proposition through complementary evidence, including human genetics, experimental changes in gene expression, and selective chemical probes. An association with disease does not by itself establish that inhibiting or activating a target will be beneficial. Phenotypic discovery instead begins with a measurable response in cells or organisms; identifying the responsible molecular target may follow rather than precede screening. (pharmacy.umich.edu)\n\nScreening tests compound collections using biochemical or cell-based assays, often in automated high-throughput formats. An initial positive result becomes a credible hit only after its activity is reproduced, its chemical identity and purity are confirmed, and concentration–response measurements support the finding. Secondary assays examine selectivity and distinguish genuine biological effects from assay interference. Hit-to-lead work then identifies chemical series whose activity can be improved through synthesis. During lead optimization, researchers repeatedly design, make, and test analogues to establish structure–activity relationships: connections between molecular changes and changes in biological activity. Altering a substituent or stereochemistry can change target recognition, while modifications elsewhere may improve solubility or metabolic stability. A lead therefore requires more than activity in the original screen; synthetic feasibility, selectivity, and preliminary evidence of target engagement also influence advancement. (ncbi.nlm.nih.gov)\n\nPharmacognosy investigates natural substances, particularly specialized metabolites from medicinal plants, fungi, bacteria, and marine organisms. Natural-product discovery commonly involves extracting source material, separating it into fractions, testing those fractions, and progressively isolating the constituent responsible for activity. Chromatography provides separation, while mass spectrometry and nuclear magnetic resonance spectroscopy contribute to structural characterization. This process distinguishes the activity of a purified molecule from that of a chemically complex extract. In 2019, the US National Cancer Institute described combining prefractionated natural-product libraries with high-throughput screening and structural analysis to make complex extracts more accessible to discovery laboratories. (pharmacognosy.us)\n\nTu Youyou’s research illustrates the connection between natural-product isolation and medicinal chemistry. Her team isolated an active crystalline constituent from Artemisia annua in November 1972, subsequently named artemisinin; chemical derivatization produced dihydroartemisinin in September 1973. Structural investigations established artemisinin as a sesquiterpene lactone containing a peroxide group, rather than a member of the previously familiar quinoline antimalarials. For preparations retained as botanical mixtures, standardization presents a different problem from isolating one compound: source identity, cultivation and collection conditions, processing, chemical profiles, and biological activity must be controlled sufficiently to obtain reproducible material. The FDA’s December 2016 botanical-drug guidance treats raw-material control, chemical testing, and manufacturing consistency as complementary elements rather than assuming that one marker constituent represents every relevant property. (nobelprize.org)\n\nSynthetic small-molecule candidates are optimized principally by changing chemical structure; biotechnology-derived candidates, including recombinant proteins and monoclonal antibodies, additionally require control of biological production and protein integrity. A landmark was the FDA’s approval of recombinant human insulin, Humulin, on October 28, 1982, following work by City of Hope and Genentech scientists in 1978. Candidate selection balances potency—the concentration required for a defined effect—with selectivity, chemical or metabolic stability, solubility, and feasible production. The most potent screened molecule is therefore not necessarily the most developable. For therapeutic proteins, aggregation and immune responses introduce additional constraints: aggregates may promote antibodies that reduce biological activity or affect safety, making stability and immunogenicity assessment part of development rather than merely final-product testing. (fda.gov)"
    },
    {
      "heading": "Drug Action, Disposition, and Individual Variation",
      "text": "Pharmacodynamics describes how drugs alter biological functions through interactions with receptors, enzymes, transporters, and other targets. Receptor agonists activate signaling, whereas antagonists inhibit activation by other ligands. Albuterol, for example, activates \\(\\beta_2\\)-adrenergic receptors on airway smooth muscle, increasing cyclic AMP and producing relaxation. Atorvastatin competitively inhibits HMG-CoA reductase, an enzyme involved in cholesterol synthesis; sertraline inhibits neuronal serotonin reuptake, illustrating action on a transporter rather than direct receptor activation. These molecular mechanisms describe initial drug–target interactions, not by themselves the magnitude or timing of clinical benefit. (accessdata.fda.gov)\n\nConcentration–response relationships distinguish potency, the concentration required for a specified effect, from maximum effect, the greatest response achievable in a particular system. Responses commonly approach a plateau as concentration increases; a lower concentration requirement does not necessarily imply greater maximum benefit. Therapeutic and toxic responses can have different concentration–response curves, and their separation helps define the range of useful exposure. Plasma concentration is also an imperfect proxy for concentration at the target, particularly when tissue distribution or downstream biological responses introduce delays. The US Food and Drug Administration’s May 2003 exposure–response guidance explicitly distinguished receptor occupancy, mechanistic biomarkers, surrogate endpoints, and clinical outcomes as different measures of response. (fda.gov)\n\nPharmacokinetics describes the time course of absorption, distribution, metabolism, and excretion, collectively termed ADME. Absorption transfers a drug from its administration site into circulation; distribution moves it between blood and tissues, with plasma-protein binding and tissue affinity influencing measured concentrations. Metabolism chemically transforms drugs, potentially producing inactive, active, or toxic metabolites, while excretion removes unchanged drug or metabolites through routes including urine and bile. For systemically acting medicines, bioavailability expresses the fraction of an administered dose reaching systemic circulation unchanged. Intravenous administration provides the reference; after oral administration, incomplete absorption and metabolism before entry into systemic circulation can reduce availability. Concentration–time profiles describe peak concentration (\\(C_{\\max}\\)), time to peak (\\(T_{\\max}\\)), and total exposure, represented by the area under the curve (AUC). (fda.gov)\n\nClearance (\\(CL\\)) expresses elimination capacity as an equivalent volume of plasma cleared per unit time. The apparent volume of distribution (\\(V_d\\)) relates the amount of drug in the body to its plasma concentration; it is a proportionality parameter, not an anatomical volume. For a one-compartment model with first-order elimination, the elimination half-life is \\(t_{1/2}=\\ln(2)V_d/CL\\). Thus, reduced clearance prolongs half-life if distribution remains unchanged. With constant clearance and repeated administration, concentrations accumulate toward a steady-state pattern rather than increasing indefinitely. These relationships require qualification when elimination becomes saturated or several tissue compartments contribute differently to distribution and terminal decline. (pmc.ncbi.nlm.nih.gov)\n\nIndividual variation can affect both exposure and sensitivity. In infancy, maturation of renal function changes elimination capacity; in older adults, organ function, body composition, disease, and concomitant medicines can contribute independently of chronological age. Pregnancy can also alter clearance: a 2007 study by Mary A. Andrew and colleagues measured mean renal clearance of amoxicillin at 24.8 litres per hour in the second trimester and 24.0 in the third, compared with 15.3 postpartum. Genetic variation supplies another mechanism: differences in the CYP2D6 gene alter conversion of codeine to morphine, and ultrarapid metabolism can produce unexpectedly high morphine exposure and respiratory depression. (fda.gov)\n\nOrgan impairment and interactions further modify these relationships. Reduced kidney function can decrease elimination of renally cleared drugs; hepatic disease can alter metabolism and systemic exposure. Other medicines may inhibit or induce metabolic enzymes or affect transporters, changing concentrations without changing the administered dose. Population models quantify associations between such characteristics, exposure, and response, but a population average or genetic category does not establish an individual patient’s outcome. Interpretation depends on the particular drug, measured organ function, concomitant medicines, and the relevant exposure–response evidence. (fda.gov)"
    },
    {
      "heading": "Pharmaceutics and Drug Delivery",
      "text": "Pharmaceutics concerns the conversion of an active drug substance into a dosage form whose composition and structure support administration and delivery. Preformulation establishes aqueous solubility, ionization across relevant pH values, particle-size distribution, solid-state form, and susceptibility to chemical degradation. Ionization can increase aqueous solubility while changing partitioning into biological membranes; these properties therefore require joint consideration. Crystalline polymorphs, hydrates, and amorphous material can differ in dissolution rate, stability, and mechanical behavior. Reducing particle size generally increases the surface area available for dissolution, although aggregation can limit this advantage. Compatibility studies examine whether excipients—the formulation’s non-active components—alter the drug through chemical reactions, moisture uptake, adsorption, or changes in its physical state. The ICH Q8(R2) pharmaceutical-development guideline, issued by the FDA in November 2009, identifies these properties as relevant to dosage-form performance. (fda.gov)\n\nTablets and capsules commonly provide solid oral doses, but their outer form does not determine their release behavior: either can contain rapidly releasing material or coated, modified-release units. Disintegration breaks a dosage form into smaller fragments; dissolution transfers drug molecules into solution. Oral solutions already contain dissolved drug and bypass dissolution of the administered solid, whereas suspensions contain dispersed particles that must dissolve before molecular absorption. Suspensions also require control of sedimentation and redispersibility to maintain dose uniformity. Creams, ointments, and gels provide semisolid vehicles for application to skin or mucosal surfaces; drug release from the vehicle and subsequent tissue penetration are separate processes. A formulation that releases drug rapidly in a laboratory diffusion cell does not necessarily deliver it rapidly through skin. (ema.europa.eu)\n\nInhaled products combine a formulation with a delivery device: nebulizers generate droplets from liquids, metered-dose inhalers produce aerosols, and dry-powder inhalers disperse particles. Their performance depends on emitted dose and aerodynamic size distribution, not simply the amount of drug in the container. For many orally inhaled products, an aerodynamic diameter of approximately \\(1–5\\,\\mu\\mathrm{m}\\) is important for pulmonary delivery; deposition also depends on airflow and device characteristics. Injectable products include solutions, suspensions, and dispersions. Intravenous solutions introduce dissolved drug directly into the circulation, whereas intramuscular or subcutaneous depots can retain drug at the administration site and release it over time. Sterility and particulate control impose additional requirements on injectable dosage forms. (fda.gov)\n\nImmediate-release formulations lack a deliberate mechanism for delaying or prolonging release; the term does not imply instantaneous dissolution or absorption. Modified-release systems deliberately alter release timing or rate. Enteric coatings resist gastric conditions and permit release later in the gastrointestinal tract, often through pH-dependent dissolution. Extended-release matrices and reservoir coatings restrict access of fluid or movement of dissolved drug. Release may involve diffusion, polymer swelling, or erosion, with several mechanisms operating together. Once released, dissolved drug must cross an epithelial barrier for systemic absorption, through passive transport or other pathways. Consequently, dissolution and membrane permeability are distinct determinants of delivery: improving one does not establish that the other has improved. (ema.europa.eu)\n\nLiposomes are vesicles formed from lipid bilayers that can incorporate drug in an aqueous interior or lipid membrane. Their size, lipid composition, encapsulated fraction, and leakage rate influence delivery. Doxil, a polyethylene-glycol-coated liposomal doxorubicin product initially approved in the United States in 1995, illustrates how a carrier can alter drug disposition; its labeling distinguishes it from other doxorubicin products rather than treating them as interchangeable. Polymer carriers provide another approach. The one-month Lupron Depot formulation encapsulates leuprolide in poly(lactic-co-glycolic acid) microspheres. A 2020 experimental study found that composition-equivalent microspheres could nevertheless have different release behavior when raw materials or preparation variables changed. (fda.gov)\n\nFormulation performance is assessed through measurements such as dissolution profiles, emitted aerosol dose, tissue permeation, and the proportions of free and encapsulated drug. These measurements characterize delivery but do not, by themselves, demonstrate superior clinical outcomes. Pharmacokinetic studies establish exposure, while comparative efficacy and safety studies address clinical benefit where required. The European Medicines Agency’s 2014 guideline on modified-release formulations explicitly separates biopharmaceutic, pharmacokinetic, efficacy, and safety investigations, with the necessary evidence depending on the drug, route, delivery system, and intended use. (fda.gov)"
    },
    {
      "heading": "Pharmaceutical Analysis and Quality Standards",
      "text": "Pharmaceutical analysis distinguishes several questions about a material or finished medicine. Identity testing establishes whether the intended substance is present; assay measures its content or strength; and purity testing controls unwanted constituents rather than demonstrating absolute chemical purity. Impurities may include synthesis by-products, residual solvents, inorganic contaminants, and degradation products formed during manufacture or storage. These require distinct measurements: an acceptable assay does not establish that every impurity is below its limit. Finished-product tests also address dosage-unit uniformity and, where appropriate, dissolution, water content, and pH. Microbiological quality is assessed according to the dosage form: nonsterile products may have limits for bacterial and fungal counts and specified objectionable organisms, while injectable products generally require sterility and bacterial-endotoxin tests. Preserved multidose formulations also require evidence that the preservative system remains effective. (fda.gov)\n\nAnalytical chemistry supplies complementary techniques rather than a single universal test. High-performance liquid chromatography separates the active substance from related compounds, permitting assay and impurity measurements; gas chromatography is useful for volatile constituents such as residual solvents. Infrared spectroscopy can support identification through a characteristic spectrum. Coupling chromatography with mass spectrometry adds mass-to-charge information to the separation, strengthening identification. ICH Q6A specifically cautions that a single chromatographic retention time is insufficiently specific as an identity test: closely related substances may behave similarly. A combined procedure, such as liquid chromatography with ultraviolet diode-array detection or mass spectrometry, provides additional discriminatory evidence. Stability-indicating assays must distinguish the substance being measured from relevant degradation products rather than count both as unchanged medicine. (fda.gov)\n\nReliable results depend on calibration, suitable reference materials, and demonstrated method performance. A reference standard is a characterized material used for comparison; its assigned content, storage conditions, and intended use matter, particularly for quantitative assays. Instrument calibration and analytical-procedure validation serve different purposes: calibration establishes the relationship between indications and reference values, whereas validation demonstrates that the complete procedure is fit for its intended analytical task. The FDA’s March 2024 adoption of ICH Q2(R2) describes validation characteristics including specificity or selectivity, accuracy, precision, reportable range, and detection or quantitation limits where relevant. Accuracy can be investigated through recovery of known additions; precision through repeated measurements within and between runs. An impurity procedure must quantify reliably near its reporting or acceptance limits, whereas an identification procedure principally needs discrimination. System-suitability checks confirm that the analytical system performs acceptably when the procedure is used. (usp.org)\n\nA pharmacopoeia publishes documentary standards, including individual monographs and general analytical chapters. USP–NF monographs specify tests for such attributes as identity, strength, purity, and performance, with designated USP reference standards supporting particular procedures. A specification, in ICH Q6A terminology, combines a list of tests, the analytical procedures, and acceptance criteria expressed as numerical limits, ranges, or other requirements. Product-specific specifications are justified using development, manufacturing, and stability evidence and approved by the relevant regulatory authority; a monograph is not an exhaustive characterization of every formulation. Specifications are one component of quality assurance, not a substitute for manufacturing controls. (usp.org)\n\nStability studies establish how quality changes with time under specified environmental conditions and support storage instructions and shelf life. ICH Q1A(R2), revised in 2003, calls for studies on at least three primary drug-product batches in the proposed market packaging. Its general-case submission framework includes at least 12 months of long-term data at \\(25 \\pm 2\\,^\\circ\\mathrm{C}\\) and \\(60 \\pm 5\\%\\) relative humidity, or \\(30 \\pm 2\\,^\\circ\\mathrm{C}\\) and \\(65 \\pm 5\\%\\), together with six months of accelerated data at \\(40 \\pm 2\\,^\\circ\\mathrm{C}\\) and \\(75 \\pm 5\\%\\). Refrigerated, frozen, and other products require different conditions. Shelf-life assignments consider assay, degradation, physical performance, and microbiological attributes—not potency alone. Packaging evaluation also examines moisture or light protection, adsorption of ingredients onto container surfaces, and substances leaching from packaging into the product. For sterile products, container-closure integrity provides evidence that the microbial barrier persists throughout storage. Accelerated results support, but do not automatically replace, long-term evidence. (fda.gov)"
    },
    {
      "heading": "Pharmaceutical Manufacturing and Industrial Pharmacy",
      "text": "Scale-up converts a laboratory or pilot process into reproducible commercial production; it is not simply multiplication of ingredient quantities. Changes in vessel geometry, loading, mixing, and heat transfer can alter product characteristics. Chemical engineering principles therefore help relate equipment settings to the physical conditions experienced by materials. ICH Q8(R2), finalized in 2009, gives the example of describing a shear-sensitive mixing operation by shear rate rather than agitation speed when a design space must apply across scales. Development studies must establish that commercial equipment preserves the relevant product attributes. (database.ich.org)\n\nFor solid oral products, blending distributes the active ingredient among excipients, but differences in particle size, density, or shape can cause subsequent segregation. Wet granulation aggregates powders using liquid and usually requires drying; dry granulation uses mechanical compaction. Milling controls granule size, and tablet presses meter material into dies before compression. Compression force and press speed can affect tablet strength, weight, and dissolution. Coating applies and dries a layer over tablets or pellets; spray delivery and drying conditions must be coordinated to obtain a consistent film. Direct compression omits granulation when material properties permit. An FDA inspection guide published in 1994 documented a dissolution failure in which a changed milling screen produced larger granules: increased tablet porosity allowed greater coating-solution penetration, slowing dissolution. (fda.gov)\n\nSterile manufacture distinguishes terminal sterilization from aseptic processing. In terminal sterilization, filled and sealed containers undergo a validated sterilization treatment. In aseptic processing, the product, containers, and closures are sterilized separately by appropriate methods and brought together under controlled conditions, without a subsequent sterilization cycle for the sealed product. FDA’s September 2004 guidance describes high-efficiency particulate air filtration, personnel gowning, environmental monitoring, and equipment controls as safeguards against microbial and particulate contamination. Aseptic process simulations, commonly called media fills, use growth medium to challenge the filling operation, including representative interventions. Finished-product sterility testing examines only a sample and cannot independently establish the sterility of every container. (fda.gov)\n\nGood manufacturing practice (GMP) establishes controls over personnel, premises, equipment, materials, production, and records. Contamination control includes cleaning procedures, appropriate separation or containment, and prevention of material and label mix-ups. Quality assurance encompasses these preventive systems, deviation investigations, and release decisions; final-product testing is one component, not a substitute for controlled manufacture. For active pharmaceutical ingredients, ICH Q7 calls for batch records identifying materials, equipment, quantities, processing dates, operators, in-process results, and deviations. The quality unit reviews critical production records and investigations before release, allowing a batch’s history to be reconstructed rather than judging it solely from laboratory results. (fda.gov)\n\nProcess validation supplies documented evidence that a process consistently delivers the intended quality. FDA’s January 2011 guidance organizes it into three stages: process design, process qualification, and continued process verification. Qualification includes assessment of facilities, utilities, and equipment, followed by process performance qualification under commercial manufacturing conditions. Continued verification evaluates production data for variation or drift after initial qualification. Quality by design, described in ICH Q8(R2), connects predefined product objectives with process understanding and risk management. Critical quality attributes are properties requiring appropriate limits or distributions, such as content uniformity or dissolution; critical process parameters are operating variables whose variability affects those attributes. Designed experiments can identify interactions and support a design space—a multidimensional combination of inputs demonstrated to assure quality. (fda.gov)\n\nICH Q10, adopted in 2008, places technology transfer and change management within a pharmaceutical quality system spanning development and commercial production. Technology transfer conveys product knowledge, manufacturing instructions, control strategies, and validation knowledge between development and production or between manufacturing sites. Change control evaluates proposed alterations—such as a new supplier, dryer, or production site—for their effects on quality and the need for additional studies or regulatory submissions. After implementation, effectiveness is assessed to confirm that the change achieved its purpose without an unintended adverse effect on product quality. (database.ich.org)"
    },
    {
      "heading": "Compounding and Preparation for Particular Patient Needs",
      "text": "Pharmaceutical compounding involves combining, mixing, diluting, or otherwise altering medicinal ingredients or existing products to create a preparation for particular clinical needs. It differs from conventional industrial manufacture of standardized, authorized products: in the United States, compounded drugs are not FDA-approved and do not undergo FDA premarket review of safety, effectiveness, and quality. Compounding also differs from routine preparation according to a marketed product’s approved instructions. Under United States Pharmacopeia (USP) Chapter 〈797〉, preparing a single dose for an individual patient according to approved labeling is not considered compounding when that labeling specifies the diluent, resulting strength, container-closure system, and storage time. Departures from those instructions can bring preparation within compounding requirements. (fda.gov)\n\nCustomization can address a strength or dosage form unavailable commercially, difficulty swallowing tablets or capsules, or an allergy to a formulation ingredient. Examples include a liquid preparation for a child unable to swallow a solid dosage form and a medicine prepared without a particular dye. USP identifies unusual dosage requirements, allergies, and rare diseases among reasons for tailored preparations. These needs concern the formulation as well as the active substance; a compounded preparation is not equivalent, merely by containing the same ingredient, to an approved generic medicine whose regulatory submission establishes the required equivalence. (fda.gov)\n\nNonsterile preparations include oral liquids, capsules, and topical semisolids; sterile preparations include products whose intended use requires freedom from viable microorganisms. Their quality controls address different but overlapping hazards. Nonsterile compounding requires controlled facilities and equipment, suitable components, trained personnel, and checks of the finished preparation. Formulation assessment includes chemical and physical stability, compatibility with the container-closure system, and the potential for microbial proliferation. Sterile compounding additionally depends on aseptic competency, appropriate engineering controls, cleaning and disinfection, and environmental monitoring. USP Chapter 〈797〉 links longer permissible storage periods to stronger controls: Category 3 preparations require sterility testing, endotoxin testing where applicable, and additional personnel and environmental safeguards. Incorrect ingredient strength and contamination are distinct threats to patient safety. (usp.org)\n\nDocumentation separates the specification for a formulation from the record of its actual preparation. USP’s revised nonsterile standards require a master formulation record for each unique formulation and a compounding record for each preparation. Release checks compare the preparation and labeling with the record, inspect physical appearance, and include other relevant tests, such as pH measurement or an assay. A beyond-use date (BUD) marks the limit assigned to a compounded preparation under specified storage conditions; it is not interchangeable with a manufacturer’s expiration date. BUD assessment considers water activity, chemical and physical stability, packaging compatibility, and microbial growth potential. For sterile preparations, supporting evidence can also include sterility, endotoxin, particulate-matter, and container-integrity testing. A shorter BUD is necessary when stability or sterility cannot be maintained for the full period otherwise permitted by the applicable category. (usp.org)\n\nThe United States provides a jurisdiction-specific distinction between patient-specific compounding and larger-scale supply. Section 503A of the Federal Food, Drug, and Cosmetic Act provides conditional exemptions from premarket approval and current good manufacturing practice requirements, including a requirement for valid patient-specific prescriptions. The Drug Quality and Security Act, enacted on November 27, 2013, added section 503B, establishing voluntarily registered outsourcing facilities that must comply with current good manufacturing practice and may supply healthcare institutions without individual patient prescriptions. These arrangements do not constitute product approval. The law followed serious compounding failures, including a 2012 outbreak involving contaminated drugs from a Massachusetts pharmacy that caused more than 750 infections and more than 60 deaths across 20 states. (fda.gov)"
    },
    {
      "heading": "Preclinical and Clinical Evaluation",
      "text": "Preclinical evaluation investigates a candidate medicine’s biological activity, disposition, and potential toxicity through laboratory experiments and, where appropriate, animal studies. Pharmacological investigations examine intended activity and unwanted effects on vital functions, including cardiovascular, respiratory, and central nervous system function. Studies of absorption, distribution, metabolism, and excretion relate administered doses to systemic exposure; toxicology studies characterize target-organ injury, dose dependence, and possible reversibility. Depending on the product and intended use, assessments include repeated-dose toxicity, genetic damage, reproductive toxicity, and carcinogenic potential. These findings inform initial human exposure and clinical monitoring, but do not establish efficacy or safety in humans. Nonclinical work continues alongside clinical development as treatment duration and exposed populations expand. ICH M3(R2), endorsed in June 2009 and issued as FDA guidance in January 2010, explicitly coordinates nonclinical studies with the scope and duration of human trials. (fda.gov)\n\nClinical development commonly distinguishes three preauthorization phases by purpose rather than by rigid participant thresholds. Phase I investigates tolerability, drug disposition, and dose–exposure relationships, often in healthy volunteers; studies of anticancer medicines commonly recruit patients instead. FDA’s illustrative ranges are 20–100 participants for Phase I, up to several hundred for Phase II, and approximately 300–3,000 for Phase III. Phase II investigates preliminary efficacy in the target condition, compares doses, and characterizes common short-term adverse effects. Phase III seeks confirmatory evidence of treatment benefit and a broader assessment of safety sufficient to evaluate the benefit–risk relationship. In the United States, an investigational new drug application supplies nonclinical findings, manufacturing information, and proposed clinical protocols before investigational testing begins. Ethics review and informed consent provide additional participant protections. (fda.gov)\n\nA randomized controlled trial compares outcomes between prospectively assigned groups. Randomization reduces systematic baseline differences, including confounding by disease severity or other patient characteristics. Blinding limits differences in management, reporting, and outcome assessment arising from knowledge of treatment assignment. A comparator may be placebo, another dose, or an established treatment; its purpose is to distinguish the investigational medicine’s effect from disease progression, expectations, and accompanying treatment. Protocols specify eligibility, follow-up, outcomes, and analysis procedures in advance. Missing observations, treatment discontinuation, and multiple outcome tests require explicit analytical handling: analyzing only participants with complete observations can bias results, while testing many outcomes without appropriate controls increases opportunities for false-positive findings. (fda.gov)\n\nEndpoints determine what a study actually demonstrates. Direct clinical outcomes measure symptoms, function, or survival; a surrogate endpoint substitutes a laboratory measurement or other marker expected to predict clinical benefit. For example, evidence from trials of blood-pressure-lowering medicines supports systolic blood pressure as a surrogate for reduced stroke risk in appropriate contexts. A marker’s response to treatment alone does not validate that substitution: validation requires evidence linking treatment-induced changes to the relevant clinical outcome. Benefit assessment is considered alongside harms, such as drug-induced liver injury, rather than inferred from efficacy measurements alone. FDA distinguishes candidate, reasonably likely, and validated surrogate endpoints according to their supporting evidence. (fda.gov)\n\nMarketing review evaluates the integrated evidence rather than merely whether a trial reached its stated endpoint. In the United States, a new drug application includes clinical and nonclinical results, manufacturing information, and proposed labeling. FDA reviewers assess effectiveness and safety for the intended use, examine whether production facilities can maintain product quality, and refine prescribing information to reflect the evidence supporting approval. Deficiencies may require additional studies or other corrective information before authorization. The approved indication and prescribing information therefore describe a particular evidentially supported use, not an unrestricted finding that the medicine is beneficial in every population or condition. (fda.gov)\n\nInitial authorization does not end evaluation. Limited preapproval exposure cannot reveal every delayed or uncommon adverse effect, and postmarketing studies can investigate unresolved risks or additional uses. Phase IV trials are one component of this continuing evidence collection, distinct from routine safety reporting. The 2007 Food and Drug Administration Amendments Act gave FDA authority to require postmarketing studies or clinical trials assessing specified serious risks. Studies required to verify clinical benefit after accelerated approval also distinguish an initial decision based on a reasonably likely surrogate from subsequent confirmation of patient benefit. New evidence can lead to revisions in prescribing information. (fda.gov)"
    },
    {
      "heading": "Community Pharmacy and Dispensing",
      "text": "Prescription dispensing begins with separate legal and clinical assessments. The legal review establishes whether the prescription meets the jurisdiction’s requirements, including prescriber authority, required particulars, validity periods, and any additional restrictions on controlled medicines. Clinical review considers the medicine, dose, dosage form, route, and treatment duration against available information about the patient’s conditions, allergies, other medicines, and relevant physiological factors. An apparently valid prescription can still require clarification before supply. The 2011 joint International Pharmaceutical Federation–World Health Organization good pharmacy practice guidelines identify assessment of prescriptions, access to relevant information, and referral beyond the pharmacist’s competence as components of quality service. (fip.org)\n\nProduct selection and assembly translate the reviewed prescription into a supply for a particular patient. Staff select the specified medicine, strength, and formulation, establish whether substitution is permitted, and prepare the required quantity or authorized pack. Labeling conveys the patient’s name, medicine details, directions, warnings, and pharmacy particulars required locally; the accuracy check compares the assembled product and label with the prescription. Documentation creates an audit trail rather than merely a payment record. A General Pharmaceutical Council practice example describes prescriptions annotated to identify the pharmacist performing clinical screening, the assistant assembling and labeling the medicine, the accuracy checker, and the person handing it out. Queries were directed to the relevant clinician, and supply occurred only after their resolution. These distinct checks address different risks: clinical appropriateness does not establish that the correct product has been selected. (fip.org)\n\nCommunication at supply explains what the medicine is for, how it is used, important precautions, and relevant adverse effects. It also identifies practical obstacles to adherence rather than assuming that missed treatment reflects unwillingness. The US Food and Drug Administration specifically identifies difficulties swallowing tablets, opening containers, reading labels, and remembering administration times as issues to discuss with pharmacists. Information about prescription and nonprescription medicines, supplements, previous reactions, and pregnancy or breastfeeding helps identify potential problems. Changes in tablet appearance can also cause confusion when different approved generic products are supplied. Unresolved prescription concerns require communication with the prescriber; presentations outside the pharmacy’s service criteria require referral, with the reason and urgency communicated through the appropriate care pathway. (fda.gov)\n\nNonprescription supply operates under different national classifications. In the United Kingdom, prescription-only medicines, pharmacy medicines, and general sales list medicines form three legal categories. Pharmacy medicines do not require a prescription but are supplied through pharmacies under pharmacist supervision; general sales list products can be sold outside pharmacies under specified conditions. Classification may depend on strength, pack size, or indication, so the same substance need not have one supply status in every presentation. In the United States, FDA regulates nonprescription products through drug applications or the over-the-counter monograph pathway and requires standardized Drug Facts labeling. These product-authorization arrangements are distinct from the professional assessment and advice accompanying a pharmacy sale. (gov.uk)\n\nEngland’s NHS Pharmacy First service illustrates a publicly commissioned consultation model alongside routine dispensing. Launched on January 31, 2024, its initial clinical pathways covered seven conditions: sinusitis, sore throat, earache, infected insect bites, impetigo, shingles, and uncomplicated urinary tract infections in women. Pharmacists assessed eligibility against defined pathways and could supply a restricted set of prescription-only medicines under patient group directions, rather than issuing an individual prescription. The pathways included self-care information, safety-netting, and referral where appropriate. NHS England reported that 9,918 pharmacies—more than 92% of those in England—had registered by January 17, 2024; registration measured intended participation, not completed consultations or clinical outcomes. (england.nhs.uk)\n\nAuthorized preventive services likewise have jurisdiction-specific boundaries. In California, Assembly Bill 1503, effective January 1, 2026, moved pharmacists’ independent initiation and administration of vaccines for people aged three years and older toward a standard-of-care practice model. The California Board of Pharmacy also distinguishes that authority from vaccine administration through collaborative practice agreements or specified prescriber orders or authorizations. Such arrangements illustrate why permission to dispense medicines, provide minor-illness consultations, and administer vaccines cannot be treated as a single universal professional scope. (pharmacy.ca.gov)"
    },
    {
      "heading": "Hospital Pharmacy and Specialized Services",
      "text": "Hospital medicine distribution combines pharmacy-controlled storage and preparation with delivery to inpatient wards, operating rooms, emergency departments, and outpatient services. In a ward-stock system, selected medicines are held locally for nursing staff to administer against authorized orders; pharmacy staff replenish stock and oversee storage conditions and expiry control. Patient-specific supply instead allocates medicines to an identified patient after order review. A unit-dose system supplies individually packaged, labeled quantities intended for a single administration, reducing bedside selection and preparation without replacing nursing checks. Central dispensaries, satellite pharmacies, and automated dispensing cabinets may operate together. The American Society of Health-System Pharmacists (ASHP) included barcode identification of unit-dose packages across preparation, dispensing, and administration in its 2013 hospital minimum-standard guidelines. These arrangements separate product supply from administration while maintaining traceability between the order, medicine, and patient. (academic.oup.com)\n\nTransfers between wards and between hospital and community care require information to move with the patient. Pharmacy participation includes establishing pre-admission medicine use, clarifying discrepancies with prescribers, and communicating the discharge regimen, including medicines started, stopped, or changed. Discharge supply and written information must correspond to the agreed treatment plan; community pharmacists and other receiving professionals need relevant information for continuing care. The International Pharmaceutical Federation’s Basel Statements, developed in 2008 and revised in a 65-statement edition launched in September 2015, explicitly address information transfer within and between care settings. They also place hospital pharmacists within multidisciplinary therapeutic decision-making teams. ASHP’s Standardize 4 Safety initiative provides a practical example of coordination: pharmacists, nurses, and physicians develop standardized intravenous and oral-liquid concentrations for settings extending from hospital to home. (fip.org)\n\nOncology services combine regimen verification with specialized preparation and handling. Pharmacy checks relate chemotherapy orders to the intended protocol, administration schedule, laboratory findings, organ function, and previous treatment exposure. Preparation and administration teams coordinate product labeling, sequencing, infusion requirements, and independent verification. Hazardous antineoplastic medicines require occupational-exposure controls throughout receipt, storage, preparation, transport, administration, and disposal—not solely inside the pharmacy’s preparation area. In intensive care, pharmacists participate in rounds and rapid therapeutic reassessment, addressing infusion compatibility, standardized concentrations, interactions, and changes in medicine disposition associated with organ failure or extracorporeal treatment. Close communication with nurses is particularly important when several continuously infused medicines share limited intravenous access. These responsibilities are described in ASHP chemotherapy guidance and the joint ASHP–American College of Clinical Pharmacy–Society of Critical Care Medicine guidance on critical-care pharmacy services. (ashp.org)\n\nPediatric services face weight-based calculations, small administration volumes, limited age-appropriate commercial formulations, and differences between neonatal, childhood, and adult medicine use. Pharmacy work includes checking the recorded weight and calculation units, selecting suitable formulations and concentrations, and coordinating preparation and discharge education with nurses and caregivers. ASHP–Pediatric Pharmacy Advocacy Group guidance identifies dilution calculations and children’s limited ability to report adverse effects as distinctive challenges. In organ transplantation, pharmacy services coordinate immunosuppressant supply, formulation selection, interaction assessment, and therapeutic drug monitoring with transplant teams and laboratories. Continuity between inpatient treatment and long-term outpatient follow-up is important because immunosuppressive regimens require sustained access and monitoring. (ashp.org)\n\nRadiopharmacy adds radiation protection to pharmaceutical quality requirements. Staff coordinate aseptic preparation, activity measurement, shielding, contamination control, and radioactive-waste handling with nuclear-medicine personnel. Short physical half-lives constrain preparation and delivery schedules: technetium-99m, widely used in diagnostic preparations, has a half-life of approximately six hours. Activity therefore has to be specified for a reference time rather than treated as a fixed quantity. The International Atomic Energy Agency’s operational guidance distinguishes levels of hospital radiopharmacy activity and their associated staffing, equipment, documentation, and quality-control requirements. Because sterility-test results cannot normally be available before administration of short-lived products, validated preparation processes and quality assurance are especially important. (iaea.org)\n\nInstitutional governance connects these services through the formulary and pharmacy and therapeutics committee. Physicians, pharmacists, and nurses assess medicines and establish policies governing selection and use; evaluations compare efficacy, safety, practical requirements, and costs with therapeutic alternatives. Investigational medicine services have a separate accountability function: records document receipt, storage, dispensing to identified research participants, returns, and final disposition. Batch or kit identifiers and inventory reconciliation allow study supplies to be traced, while restricted access to treatment assignments preserves blinding where required. Pharmacy staff coordinate these records and protocol-specific handling with investigators, research nurses, sponsors, and monitors rather than treating investigational products as ordinary ward stock. (ashp.org)"
    },
    {
      "heading": "Clinical Pharmacy and Pharmaceutical Care",
      "text": "Clinical pharmacy is a practice and research discipline concerned with the rational use of medicines and the application of pharmaceutical knowledge to patient care. The American College of Clinical Pharmacy’s definition, published in 2008, emphasizes optimizing medication therapy and promoting health and disease prevention; its scope is not restricted to hospitals. Pharmaceutical care is a patient-centered model of professional responsibility: the pharmacist identifies an individual’s medicine-related needs, helps implement a care plan, and evaluates its outcomes. Charles D. Hepler and Linda M. Strand’s influential 1990 formulation connected responsible provision of drug therapy with definite outcomes that improve quality of life. In 1998, the International Pharmaceutical Federation extended this goal to improving or maintaining quality of life. The distinction is therefore between a discipline supplying clinical expertise and a model specifying how responsibility for an individual patient’s medicine-related outcomes is organized. (accp.com)\n\nA medication history establishes what a patient actually takes, rather than merely reproducing a prescription list. It records prescribed medicines, nonprescription products and complementary preparations, their strength, dose, route and frequency, together with actual use, previous adverse reactions and relevant allergies. Patient or caregiver accounts are compared with available prescribing, dispensing and clinical records. Medication reconciliation then compares the verified history with the medicines ordered at a transition of care, identifies discrepancies, resolves them and documents changes. An omitted long-term medicine or a conflicting dose requires clarification; a documented intentional discontinuation is not necessarily an error. Reconciliation establishes an accurate, communicated list, whereas medication review evaluates whether the treatment itself remains appropriate. England’s NICE guideline NG5, published in March 2015, specifies reconciliation within 24 hours of admission to an acute setting, or sooner when clinically necessary, by a trained and competent health professional—not exclusively a pharmacist. (accp.com)\n\nStructured medication review examines each medicine against its indication, therapeutic goal, effectiveness, safety and practical usability, while considering the complete regimen and the patient’s priorities. Medicine-related problems can include treatment without an indication, an untreated condition requiring therapy, inadequate effectiveness, adverse effects, interactions, or difficulty taking treatment as intended. Assessment incorporates clinical findings, laboratory results and the patient’s experience; it also distinguishes an unsuitable regimen from barriers such as affordability or misunderstanding. The resulting care plan records the problem, the proposed action and its rationale, agreed goals, monitoring parameters and a follow-up interval. ACCP’s 2014 standards describe this as collaborative work with patients and other professionals. Authority to initiate, modify or discontinue therapy depends on applicable law, collaborative agreements and institutional privileges. (nice.org.uk)\n\nTherapeutic monitoring tests whether the agreed goals are being achieved without unacceptable harm. The WHO–FIP handbook Developing Pharmacy Practice describes monitoring plans that identify what to measure, how often to measure it and when treatment should be reassessed. Examples include blood-pressure measurements, blood glucose, electrolyte results and blood concentrations of selected medicines. These measurements complement, rather than replace, assessment of symptoms, adverse effects and medicine-taking behavior. Follow-up may reveal a new problem, insufficient response or a change in clinical circumstances, leading to reassessment of the care plan. Communication includes explaining the plan to patients and caregivers in understandable terms and conveying recommendations, decisions and unresolved issues to the responsible clinicians. (fip.org)\n\nDocumentation makes this continuing responsibility visible. ACCP’s standards specify recording the medication history, assessment, proposed or implemented actions, monitoring arrangements and follow-up in the medical record; a SOAP note organizes information as subjective findings, objective findings, assessment and plan. Outcome evaluation extends beyond counting reviews or recommendations: the WHO–FIP handbook identifies disease control, symptom reduction, prevention of illness and preservation of quality of life as relevant goals. Clinical measurements and patient-reported experiences answer different questions—a laboratory result may indicate therapeutic response, while the patient’s account identifies treatment burden or persistent symptoms. Recording both allows subsequent encounters to assess progress against the original goals and revise the plan when necessary. (accp.com)"
    },
    {
      "heading": "Medication Safety and Pharmacovigilance",
      "text": "An adverse event is an untoward medical occurrence during medicine use, without necessarily implying that the medicine caused it. An adverse drug reaction is a harmful, unintended response for which a causal relationship is at least reasonably suspected; “suspected” does not mean proven. A medication error is an unintended failure in the treatment process that causes, or could cause, harm, including mistakes in prescribing, preparation, dispensing, storage, or administration. Errors need not produce injury, and adverse reactions can occur without an error. Product-quality problems, such as contamination, defective packaging, labeling mix-ups, or instability, concern the product itself and may be detected before anyone is harmed. These categories overlap: a labeling defect can contribute to an administration error and subsequent adverse reaction. (fda.gov)\n\nPharmacovigilance encompasses the detection, assessment, understanding, and prevention of adverse effects and other medicine-related problems. It complements preauthorization trials, whose selected populations and limited observation periods may not reveal rare or delayed effects. Spontaneous reporting collects suspicions from patients and health professionals; in the United States, MedWatch accepts voluntary reports of adverse events, product-quality problems, and use errors. Manufacturers also submit safety reports under regulatory requirements. Pharmacists can contribute clinical histories and identify suspect batches: one FDA example describes a pharmacist finding glass fragments in diphenhydramine syrup, followed by investigation of bottle production and a nationwide recall. (who.int)\n\nA report is evidence warranting assessment, not proof of causation. Underlying illness, concurrent medicines, or unrelated events may explain an apparent association. Spontaneous-report databases contain incomplete and duplicate records, while underreporting and the absence of a reliable exposed-population denominator prevent report counts from establishing incidence. Active surveillance instead systematically examines defined healthcare datasets. FDA launched its Sentinel Initiative in May 2008; the resulting distributed network queries routinely collected electronic healthcare data to investigate safety questions. Such data support comparative analyses, but exposure definitions, outcome ascertainment, and confounding still require careful treatment. (fda.gov)\n\nSignal detection identifies information suggesting a previously unrecognized association, or a new aspect of a known association, that merits investigation. Sources include spontaneous reports, clinical studies, and scientific literature. Statistical screening can flag drug–event combinations reported disproportionately often, but clinical assessment remains necessary. Investigators review individual cases, remove duplicates, apply consistent case definitions, and examine timing, plausible mechanisms, alternative explanations, and whether symptoms changed after treatment withdrawal or re-exposure. European Medicines Agency guidance distinguishes detection from validation and further assessment; its Pharmacovigilance Risk Assessment Committee evaluates signals and issues recommendations, including changes to product information when justified. (ema.europa.eu)\n\nSystem-level prevention addresses the conditions that allow errors rather than relying solely on individual vigilance. High-alert medicines, including insulin, anticoagulants, and chemotherapy, carry a heightened risk of significant injury when used incorrectly. Safeguards include standardized orders and concentrations, controlled storage, barcode verification, selected independent checks, and defined monitoring responsibilities. The Institute for Safe Medication Practices’ high-alert assessment examines safeguards across prescribing, preparation, dispensing, administration, and follow-up. The World Health Organization launched Medication Without Harm in Bonn on 29 March 2017, setting an initial target of reducing severe, avoidable medication-related harm globally by 50% within five years. Its three priority areas were high-risk situations, polypharmacy, and transitions of care; the target was an intended reduction, not a reported achievement. (ismp.org)\n\nPolypharmacy requires assessment of the appropriateness of the whole regimen, rather than assuming that multiple medicines are inherently inappropriate. WHO’s 2019 technical report emphasizes patient participation, multidisciplinary review, and organizational leadership. At admission, internal transfer, and discharge, safety depends on an accurate medication history and explicit communication of changes. WHO’s transitions-of-care report specifies interviewing the patient, checking at least one reliable information source, reconciling and updating the medication list, and communicating it to the patient and subsequent providers. These processes address information discontinuities; evaluating their effectiveness requires patient-level outcomes as well as counts of corrected discrepancies. (who.int)"
    },
    {
      "heading": "Public Health and Responsible Medicine Use",
      "text": "Pharmacy contributions to public health include improving understanding of medicines, supporting disease prevention, and connecting people with primary health care. The 2011 joint guidelines on good pharmacy practice issued by the International Pharmaceutical Federation (FIP) and the World Health Organization identify public-health participation as one of four principal professional roles. They specify that medicine information should be evidence-based, understandable, objective, and non-promotional, with educational materials adapted to different ages and levels of health literacy. Practical activities include explaining medicine instructions, helping patients assess online health claims, and providing information that supports participation in care decisions. Preventive services identified in the guidelines include smoking-cessation support, infectious-disease education, and, where applicable, point-of-care testing and screening for people at increased disease risk. These activities require collaboration with other health professionals rather than treating a pharmacy encounter as a substitute for comprehensive medical assessment. (who.int)\n\nVaccination illustrates how pharmacy-based prevention depends on specifically authorized professional activities. Pharmacists may provide information and referral even where they cannot administer vaccines; administration requires the relevant legal authority, training, and service arrangements. A dated United States example is the September 3, 2020 federal guidance under the Public Readiness and Emergency Preparedness Act, which authorized state-licensed pharmacists, subject to specified conditions, to order and administer FDA-authorized or licensed COVID-19 vaccines to people aged three years or older. Subsequent 2020 guidance concerning supervised pharmacy technicians and interns required practical injection training, recognition of emergency vaccine reactions, and current cardiopulmonary-resuscitation certification. It also required supervising pharmacists to review vaccination records, meet registry-reporting requirements, and inform the primary-care provider when available, linking the pharmacy service to continuing care. (hhs.gov)\n\nAntimicrobial stewardship concerns measuring and improving antimicrobial prescribing and use, including preventing unnecessary treatment while avoiding delayed or inadequate treatment of infections that require it. Pharmacy participation includes checking antibiotic prescriptions for allergies and interactions, communicating questions to prescribers, and explaining appropriate use and anticipated adverse effects. The US Centers for Disease Control and Prevention’s 2016 outpatient stewardship report, authored by Guillermo V. Sanchez, Katherine E. Fleming-Dutra, Rebecca M. Roberts, and Lauri A. Hicks, cited an estimate that at least 30% of US outpatient antibiotic prescriptions were unnecessary. Its framework comprised four elements: commitment, action for policy and practice, tracking and reporting, and education and expertise. Pharmacists were identified as partners alongside prescribers and microbiology laboratories; local susceptibility summaries could inform treatment guidance, while prescribing data and feedback could identify departures from recommended practice. The objective was appropriate selection, dose, and duration—not simply reducing the total number of prescriptions—and limiting harms associated with unnecessary exposure and antibiotic resistance. (cdc.gov)\n\nDuring outbreaks and emergencies, maintaining essential medicine services is distinct from treating the outbreak disease in individual patients. FIP’s guidance updated on July 14, 2020 described pharmacy responsibilities during COVID-19 that included continued medicine supply, reliable public information, infection prevention, and referral. Operational measures included arranging replacement professional supervision, reducing crowding, using remote prescription-refill arrangements, and delivering medicines to people confined at home. Continuity extended to maintenance treatment for long-term noncommunicable diseases, not only medicines associated with COVID-19. Hospital pharmacy responsibilities included coordinating medicine availability with clinical teams and supporting safe medicine use. The guidance distinguished these functions from disease treatment: pharmacies and primary-care facilities without the necessary environment and equipment were not appropriate settings for managing COVID-19 patients. (fip.org)"
    },
    {
      "heading": "Medicines Supply, Access, and Economic Evaluation",
      "text": "Medicines procurement connects product selection with demand forecasting, supplier assessment, contracting, and delivery. Forecasts may use historical consumption, estimates of disease frequency and treatment requirements, or adjusted consumption from comparable populations; past use alone can underestimate need where stock-outs have suppressed dispensing. Procurement specifications identify the medicine, strength, dosage form, quality requirements, quantities, and delivery schedule. Competitive purchasing therefore involves assessing qualified suppliers rather than simply accepting the lowest unit price. WHO’s procurement guidance treats quality assurance and reliable supply as integral to purchasing, while its medicines-management cycle links selection, quantification, procurement, storage, and distribution. (iris.who.int)\n\nInventory management balances continuity of supply against expiry, storage costs, and overstocking. Reorder points incorporate forecast consumption during replenishment lead time and buffer stock; stock records track receipts, issues, quantities, and expiry dates. First-expiry-first-out rotation gives priority to otherwise identical products with the earliest expiry. Distribution requires documented handling and suitable storage throughout transport and warehousing, not merely at the pharmacy. A cold chain maintains product-specific temperature conditions: CDC specifies \\(2–8\\,^\\circ\\mathrm{C}\\) for vaccines licensed for refrigerator storage, while other vaccines require different conditions. Monitoring matters because exposure to freezing can permanently reduce the potency of liquid vaccines containing aluminum adjuvants. (emanual.who.int)\n\nShortages can arise from manufacturing failures, commercial withdrawal, and difficulties expanding replacement production. An FDA analysis reported in October 2019 examined 163 medicines entering shortage during 2013–2017 and attributed 62% of those shortages to quality problems; its broader investigation also identified weak incentives to produce less-profitable medicines and inadequate market rewards for robust quality systems. Supply-chain traceability serves a different purpose: documenting product identity and transactions so that suspect products can be investigated. In the United States, the Drug Supply Chain Security Act, signed on November 27, 2013, established tracing requirements for most finished human prescription medicines. Package identifiers combine a product code and unique serial number with the lot number and expiry date, while transaction information connects manufacturers, wholesalers, and dispensers. (fda.gov)\n\nEssential medicines are selected to meet a population’s priority health-care needs, considering disease prevalence, evidence of efficacy and safety, and comparative cost-effectiveness. The World Health Organization introduced its Model List in 1977 and updates it every two years; a separate children’s list began in 2007. The Model List guides national adaptation rather than imposing an identical purchasing catalogue on every country. National lists and institutional formularies translate selection into procurement, supply, and reimbursement arrangements. WHO reports that more than 150 countries have adopted national lists based on its model. Inclusion does not itself guarantee availability or payment, and high absolute cost does not automatically exclude a medicine that meets the selection criteria. (who.int)\n\nAffordability concerns both household payments and health-system budgets. Financing combines taxation, prepaid insurance, external assistance, and direct out-of-pocket payments; pooling prepaid funds spreads financial risk rather than leaving each patient to meet the entire cost when illness occurs. Coverage depends on benefit design and purchasing arrangements as well as the existence of insurance. Access inequalities also reflect infrastructure and delivery capacity: a low-priced medicine may remain inaccessible where reliable distribution is absent. Taxes, tariffs, and supply-chain mark-ups can further separate the procurement price from the amount paid by patients. These financial and physical barriers are distinct dimensions of universal health coverage. (who.int)\n\nCost-effectiveness analysis compares alternatives through their additional costs and health outcomes. Cost–utility analysis commonly expresses outcomes in quality-adjusted life years (QALYs), combining survival with health-related quality of life. Its incremental ratio is \\(ICER=(C_1-C_0)/(E_1-E_0)\\), where \\(C\\) denotes costs and \\(E\\) denotes effects. Relevant costs can include administration and monitoring, not just acquisition. Budget-impact analysis instead estimates the expenditure associated with implementation, incorporating eligible population, uptake, and local costs over a specified period. Thus, good value per health gain and manageable total expenditure are separate questions. Such evaluations inform population-level funding and resource allocation; they do not determine an individual patient’s clinical response or replace clinical assessment. (nice.org.uk)"
    },
    {
      "heading": "Regulation and Professional Ethics",
      "text": "Pharmacy regulation separates three objects of oversight: medicinal products, premises and organizations supplying them, and individual practitioners. In the United States, the Food and Drug Administration (FDA) regulates prescription and nonprescription drug products, while state authorities license pharmacies and pharmacy personnel. California, for example, maintains distinct facility licenses for pharmacies and personal licenses for pharmacists, intern pharmacists, and pharmacy technicians. Product authorization therefore does not establish that a particular supplier or practitioner is licensed to provide pharmacy services. Federal controlled-substance requirements add another layer, administered by the Drug Enforcement Administration (DEA). (fda.gov)\n\nGreat Britain combines premises and professional oversight within the General Pharmaceutical Council (GPhC), whose jurisdiction covers England, Scotland, and Wales rather than the whole United Kingdom. It regulates pharmacists, pharmacy technicians, and registered pharmacies, sets professional standards, inspects premises, and investigates concerns about fitness to practise. Pharmacy owners are accountable for meeting premises standards, including safe management, suitable staffing, protection of confidential information, and appropriate facilities. Individual accountability remains distinct: the GPhC’s nine professional standards, published in May 2017, apply to pharmacists and pharmacy technicians across practice settings, including roles without direct patient contact. Its regulatory functions include restricting practice when necessary to protect patients and the public. (assets.pharmacyregulation.org)\n\nLegal supply categories determine how medicines may reach patients, but their structure differs between jurisdictions. The FDA distinguishes prescription drugs from nonprescription, or over-the-counter, drugs; nonprescription products may enter the market through an approved drug application or the OTC monograph pathway. United Kingdom rules distinguish prescription-only medicines (POM), pharmacy medicines (P), and general sale list medicines (GSL). Pharmacy medicines do not require a prescription but are ordinarily supplied through a pharmacy under pharmacist supervision, whereas GSL products may be sold in general retail outlets. Classification can depend on strength, pack size, indication, or intended users: the same active substance may consequently appear in more than one category. Prescription requirements also have defined statutory exemptions rather than functioning as an absolute prohibition on every other form of supply. (fda.gov)\n\nControlled-medicine safeguards operate in addition to ordinary prescription rules. The DEA’s 2022 Pharmacist’s Manual describes pharmacy registration, secure storage, inventories, recordkeeping, and reporting obligations intended to prevent diversion while permitting lawful medical supply. Under United States federal rules, Schedule II prescriptions cannot be refilled; prescriptions for Schedule III and IV substances may generally receive no more than five refills within six months. A controlled-substance prescription must be issued for a legitimate medical purpose by a practitioner acting within usual professional practice. The dispensing pharmacist has a corresponding responsibility for its legitimacy: possession of a prescription does not, by itself, discharge that responsibility. State law may impose additional restrictions. (deadiversion.usdoj.gov)\n\nConfidentiality and consent concern different professional obligations. Confidentiality governs the handling and disclosure of information; consent concerns a person’s agreement to care or services. The GPhC standards require consent for pharmacy care, involvement of patients in decisions, communication adapted to their needs, and checks that information has been understood. Their privacy requirements include secure information management and avoiding identifiable conversations that can be overheard by people uninvolved in care. Confidentiality continues after death. These duties extend beyond electronic records to consultation spaces, telephone conversations, and team conduct. (assets.pharmacyregulation.org)\n\nPublished professional codes connect these regulatory duties with ethical obligations. The American Pharmacists Association’s Code of Ethics for Pharmacists, adopted on October 27, 1994, establishes commitments to patient welfare, autonomy, understandable communication, truthfulness, competence, and equitable allocation of resources. It also rejects conduct or working conditions that impair professional judgment or compromise patients’ interests. The GPhC’s 2017 standards make professional independence operational by requiring practitioners to declare and manage personal or professional interests, and to ensure organizational incentives or targets do not displace patients’ needs. They additionally require openness when things go wrong, raising concerns about unsafe practice, and learning from incidents—linking individual accountability to patient safety rather than merely to completion of a dispensing transaction. (pharmacist.com)"
    },
    {
      "heading": "Education, Research Training, and the Workforce",
      "text": "Professional pharmacy education prepares graduates for regulated practice, whereas research degrees in pharmaceutical sciences prepare investigators in drug discovery, formulation, delivery, and medicine-use research. In the United States, the Doctor of Pharmacy (PharmD) normally comprises four professional academic years following at least two years of undergraduate study, although program structures vary. The degree does not itself confer a license: the North American Pharmacist Licensure Examination assesses general practice competence, while individual boards determine additional requirements. In Great Britain, the usual university route is a four-year Master of Pharmacy (MPharm), entered from secondary-school qualifications or equivalents, followed by supervised foundation training and a registration assessment. The General Pharmaceutical Council’s 2024/25 training manual specified at least 52 weeks of full-time foundation training and at least four supervisor sign-offs. These routes differ in both entry level and the placement of supervised practice within the qualification pathway. (aacp.org)\n\nResearch-oriented master’s and PhD programs are distinct from these professional qualifications. Their subjects include medicinal chemistry, pharmaceutics, pharmacology, pharmacogenetics, and health outcomes. Admission need not presuppose pharmacist registration: the University of Michigan’s pharmaceutical sciences PhD accepts applicants with a US bachelor’s degree or its equivalent. Its curriculum illustrates research training through laboratory rotations, selection of a research supervisor, coursework in biosciences and statistics, research ethics, a defended dissertation proposal, and a dissertation defense. It also requires an accepted first-authored peer-reviewed article before the defense. Such assessment demonstrates research competence rather than eligibility to dispense medicines. (aacp.org)\n\nProfessional curricula connect foundational sciences with therapeutic reasoning, communication, and practical performance. The US Accreditation Council for Pharmacy Education’s standards, effective July 1, 2025, require integrated biomedical, pharmaceutical, social and administrative, and clinical sciences. They specify at least 300 hours of introductory pharmacy practice experience and 36 weeks, or 1,440 hours, of advanced experience. Required advanced placements encompass community pharmacy, ambulatory care, hospital or health-system pharmacy, and inpatient adult care. Supervised placements therefore assess application of knowledge in actual practice rather than examination performance alone. Interprofessional education additionally involves learning about, from, and with other healthcare professions; the standards require participation in team-based patient care and therapeutic decision-making. (acpe-accredit.org)\n\nPostqualification development serves different purposes from initial registration. US postgraduate year-one pharmacy residencies consolidate practice competencies; postgraduate year-two residencies build on them in more focused fields. ASHP-accredited residencies require at least one year each, so completing both ordinarily entails two years of additional training. Continuing professional development is a form of lifelong learning linked to maintaining competence in a practitioner’s actual work. Under Great Britain’s revalidation framework published in January 2018, annual submissions comprise four development records, including at least two planned learning activities, one peer discussion, and one reflective account. Records must describe relevance to practice and benefits for people using the professional’s services, rather than merely documenting attendance at courses. (ashp.org)\n\nThe workforce includes distinct occupational groups. Pharmacists hold practice qualifications and registration or licensure; pharmaceutical scientists conduct research and may qualify through scientific rather than professional pharmacy degrees. Pharmacy technicians undertake technical and organizational tasks, including medicine preparation, inventory work, and prescription processing, with responsibilities determined by jurisdiction. US technician entry routes include workplace training or postsecondary programs, and most states regulate the occupation. Specialized technician roles include sterile preparation and medication-history collection. Technicians are also distinct from other support personnel, whose work may include administrative or retail functions. (aacp.org)\n\nWorkforce comparisons require dated denominators and attention to geography and skill mix. FIP’s 2025 global workforce review reported that its 2022 data cycle covered 5.5 million pharmacists and 0.68 million technicians and assistants across 83 countries, representing approximately 71% of the world’s population. The review reported average pharmacist densities of 12.1 per 10,000 inhabitants in high-income countries and 3.8 in low-income countries. Its reported sector distribution was concentrated in community settings, at 77%, compared with 10% in hospitals and 4% in pharmaceutical industry. These national and international aggregates do not establish local availability: FIP’s earlier workforce and migration study separately documented rural–urban distribution disparities, illustrating why workforce planning considers location as well as total numbers. (fip.org)"
    },
    {
      "heading": "Digital Technologies and Environmental Sustainability",
      "text": "Electronic prescriptions transmit structured medication orders between prescribing and dispensing systems, while shared medication records allow clinicians and pharmacists to retrieve medication histories across care settings. These functions are related but distinct: transmitting an order does not establish that a medicine was dispensed or taken. United States interoperability guidance recommends requesting medication histories from applicable sources and reconciling them with the clinical record. Clinical decision support uses patient-specific information to present interaction warnings, allergy checks, reminders, or order sets within the workflow; it supplies information for decisions rather than independently conferring prescribing authority. (healthit.gov)\n\nDispensing automation combines controlled storage, machine-readable identification, and electronic transaction records. Automated cabinets can restrict access through locked compartments, while barcode scanning compares selected products with recorded orders. In ASHP’s 2023 survey of United States hospitals, 73.6% used machine-readable coding to verify doses during pharmacy dispensing, and 86% used decentralized automated distribution. Telepharmacy instead describes pharmacists’ use of telecommunications to provide care or oversee operations remotely: examples include medication-order review, patient counseling, and image-based verification of preparations. The equipment enables these activities, but licensure, supervision requirements, and institutional authorization determine who may perform them; ASHP’s 2022 statement documented variation among state regulatory arrangements. (news.ashp.org)\n\nComputational applications extend beyond dispensing. Artificial intelligence and machine learning are investigated for compound screening and design, prediction of patient outcomes, analysis of clinical datasets, and pharmaceutical manufacturing. Adoption in routine practice is uneven: the same 2023 ASHP survey reported advanced analytics, including AI and predictive analytics, in 5.7% of hospitals, compared with basic analytics in 87.3%. On January 6, 2025, the FDA issued draft guidance proposing a risk-based credibility framework for AI-generated evidence supporting drug regulatory decisions, drawing on experience with more than 500 submissions containing AI components since 2016. Its central distinction was the model’s specific context of use: performance adequate for exploratory analysis need not establish credibility for a regulatory decision. (fda.gov)\n\nValidation therefore concerns the intended population, input-data quality, and consequences of incorrect outputs, rather than predictive accuracy alone. WHO’s 2021 guidance on AI governance identifies human control, transparency, accountability, and equitable access as core principles, and warns against transferring systems trained in one setting without considering differences in other populations. Data privacy and confidentiality remain relevant when medication records are pooled or reused. Accessibility also encompasses affordability, disability, connectivity, and digital literacy: remote services can extend geographical reach while excluding people unable to use their interfaces. FIP’s 2021 report on digital health in pharmacy education accordingly treats workforce training and organizational capacity as prerequisites for implementation, not incidental additions to software acquisition. (who.int)\n\nEnvironmental responsibilities span manufacturing emissions, distribution, medicine use, and waste management. Antibiotic residues released through manufacturing wastewater can promote antibiotic resistance; WHO’s September 3, 2024 guidance established a scientific basis for discharge targets, risk management, auditing, and public transparency, rather than creating globally binding limits. At the use stage, product characteristics matter: NHS England reported that inhalers accounted for approximately 3% of its carbon footprint, largely because of metered-dose inhaler propellants. Its respiratory-care programme combines clinically appropriate product selection with technique assessment and disposal arrangements, rather than treating carbon intensity as the sole selection criterion. (who.int)\n\nImplemented waste measures include organized collection of unused medicines: the United States DEA reported 629,953 pounds collected in association with its October 26, 2024 National Prescription Drug Take Back Day. FIP’s environmental policy, adopted on September 24, 2023, recommends inventory controls to reduce expiry-related waste, sustainable procurement, manufacturing wastewater monitoring, and incorporation of environmental sustainability into pharmacy curricula and continuing professional development. These recommendations are not evidence of universal implementation. Their educational content includes medicine-related pollution, healthcare decarbonization, and climate-related disruption of storage and supply, connecting environmental knowledge with identifiable pharmacy operations. (dea.gov)"
    }
  ],
  "links": [
    "chemistry",
    "biology",
    "pharmacology",
    "health-system",
    "public-health",
    "medicine",
    "world-health-organization",
    "mesopotamia",
    "ancient-egypt",
    "traditional-chinese-medicine",
    "islamic-golden-age",
    "penicillin",
    "organic-chemistry",
    "enzyme",
    "protein",
    "genetics",
    "stereochemistry",
    "plant",
    "fungi",
    "bacteria",
    "chromatography",
    "mass-spectrometry",
    "spectroscopy",
    "monoclonal-antibody",
    "insulin",
    "pharmacokinetics",
    "metabolism",
    "half-life",
    "pregnancy",
    "gene",
    "kidney",
    "ph",
    "diffusion",
    "polymer",
    "solvent",
    "analytical-chemistry",
    "calibration",
    "chemical-engineering",
    "experimental-design",
    "allergy",
    "informed-consent",
    "randomized-controlled-trial",
    "randomization",
    "confounding",
    "vaccine",
    "chemotherapy",
    "organ-transplantation",
    "quality-of-life",
    "causation",
    "primary-health-care",
    "antibiotic-resistance",
    "temperature",
    "insurance",
    "universal-health-coverage",
    "law",
    "data-privacy",
    "ethics",
    "masters-degree",
    "doctor-of-philosophy",
    "bachelors-degree",
    "statistics",
    "lifelong-learning",
    "automation",
    "artificial-intelligence",
    "machine-learning"
  ],
  "sources": [
    {
      "title": "What is pharmacology? - British Pharmacological Society",
      "url": "https://www.bps.ac.uk/careers-education/what-is-pharmacology/"
    },
    {
      "title": "Home - Pharmaceutical Sciences",
      "url": "https://pharmacy.wisc.edu/pharmsci/"
    },
    {
      "title": "Admissions - Pharmaceutical Sciences",
      "url": "https://pharmacy.wisc.edu/pharmsci/admissions/"
    },
    {
      "title": "BPS Undergraduate Curriculum in Clinical Pharmacology, Therapeutics and Prescribing",
      "url": "https://www.bps.ac.uk/fileadmin/uploads/bps/Documents/Education/Clinical_Pharmacology__Therapeutics_and_Prescribing_Curriculum_for_Medical_Degrees.pdf"
    },
    {
      "title": "Pharmacists : Occupational Outlook Handbook",
      "url": "https://www.bls.gov/ooh/healthcare/pharmacists.htm"
    },
    {
      "title": "Pharmacy Technicians : Occupational Outlook Handbook",
      "url": "https://www.bls.gov/OOH/healthcare/pharmacy-technicians.htm"
    },
    {
      "title": "The Drug Development Process",
      "url": "https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process"
    },
    {
      "title": "How do I go about getting a drug approved?",
      "url": "https://www.fda.gov/industry/fda-basics-industry/how-do-i-go-about-getting-drug-approved"
    },
    {
      "title": "Joint FIP/WHO guidelines on good pharmacy practice: standards for quality of pharmacy services",
      "url": "https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/distribution/trs961-annex8-fipwhoguidelinesgoodpharmacypractice.pdf"
    },
    {
      "title": "History of pharmacy",
      "url": "https://en.wikipedia.org/wiki/History_of_pharmacy"
    },
    {
      "title": "Papyrus Ebers — English",
      "url": "https://sae.saw-leipzig.de/en/documents/papyrus-ebers?version=445"
    },
    {
      "title": "Greek Medicine",
      "url": "https://mainweb.awsprod.nlm.nih.gov/hmd/topics/greek-medicine/index.html"
    },
    {
      "title": "Traditional Chinese Medicine",
      "url": "https://www.nlm.nih.gov/hmd/topics/chinese-traditional/index.html"
    },
    {
      "title": "Charaka Samhita",
      "url": "https://en.wikipedia.org/wiki/Charaka_Samhita"
    },
    {
      "title": "Islamic Medical Manuscripts, Pharmaceutics 1",
      "url": "https://mainweb.awsprod.nlm.nih.gov/hmd/arabic/pharmaceutics1.html"
    },
    {
      "title": "Islamic Medical Manuscripts: Bio-Bibliographies - G",
      "url": "https://www.nlm.nih.gov/hmd/arabic/bioG.html"
    },
    {
      "title": "An Odyssey of Knowledge - The Spread of Translation",
      "url": "https://www.nlm.nih.gov/exhibition/odysseyofknowledge/spreadoftranslation.html"
    },
    {
      "title": "Apothecaries Timeline - Society of Apothecaries",
      "url": "https://www.apothecaries.org/timeline/"
    },
    {
      "title": "Who we are - Society of Apothecaries",
      "url": "https://www.apothecaries.org/who-we-are/"
    },
    {
      "title": "Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK92015/"
    },
    {
      "title": "Drug Discovery and Development for Pain",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK57262/"
    },
    {
      "title": "About the ASP",
      "url": "https://pharmacognosy.us/about-the-asp/"
    },
    {
      "title": "Discovering New Cancer Drugs from Nature - NCI",
      "url": "https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-drugs-natural-products-nci-program"
    },
    {
      "title": "Tu Youyou – Biographical",
      "url": "https://www.nobelprize.org/prizes/medicine/2015/tu/biographical/"
    },
    {
      "title": "Botanical Drug Development Guidance for Industry",
      "url": "https://www.fda.gov/files/drugs/published/Botanical-Drug-Development--Guidance-for-Industry.pdf"
    },
    {
      "title": "100 Years of Insulin",
      "url": "https://www.fda.gov/about-fda/fda-history-exhibits/100-years-insulin"
    },
    {
      "title": "Immunogenicity Assessment for Therapeutic Protein Products",
      "url": "https://www.fda.gov/media/85017/download"
    },
    {
      "title": "Albuterol Sulfate Prescribing Information",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205636s020lbl.pdf"
    },
    {
      "title": "ATORVALIQ Prescribing Information",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/213260Orig1s000lbl.pdf"
    },
    {
      "title": "ZOLOFT Prescribing Information",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/019839s100%2C020990s057lbl.pdf"
    },
    {
      "title": "Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applications",
      "url": "https://www.fda.gov/media/71277/download"
    },
    {
      "title": "Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling Methods",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3917320/"
    },
    {
      "title": "Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products — Content and Format",
      "url": "https://www.fda.gov/media/74346/download?attachment="
    },
    {
      "title": "A Simple Methodology to Differentiate Changes in Bioavailability from Changes in Clearance Following Oral Dosing of Metabolized Drugs",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7478330/"
    },
    {
      "title": "Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5846051/"
    },
    {
      "title": "Introduction to Quantitative Pharmacology",
      "url": "https://onlinepc.pharmacy.ufl.edu/programs/courses/introduction-to-quantitative-pharmacology/"
    },
    {
      "title": "General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products",
      "url": "https://www.fda.gov/media/90358/download"
    },
    {
      "title": "ICH E7: Studies in Support of Special Populations—Geriatrics",
      "url": "https://www.fda.gov/media/71317/download"
    },
    {
      "title": "Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies",
      "url": "https://pubmed.ncbi.nlm.nih.gov/17329990/"
    },
    {
      "title": "Q8(R2) Pharmaceutical Development",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q8r2-pharmaceutical-development"
    },
    {
      "title": "Guidance for Industry: Pharmaceutical Solid Polymorphism",
      "url": "https://www.fda.gov/media/71375/download"
    },
    {
      "title": "Oral Solutions and Suspensions (8/94)",
      "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/oral-solutions-and-suspensions-894"
    },
    {
      "title": "Guideline on quality of oral modified release products",
      "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-oral-modified-release-products_en.pdf"
    },
    {
      "title": "Guidance for Industry: Nonsterile Semisolid Dosage Forms",
      "url": "https://www.fda.gov/media/71141/download"
    },
    {
      "title": "FY2016 Regulatory Science Report: Topical Dermatological Drug Products",
      "url": "https://www.fda.gov/industry/generic-drug-user-fee-amendments/fy2016-regulatory-science-report-topical-dermatological-drug-products"
    },
    {
      "title": "Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reviewer-guidance-nebulizers-metered-dose-inhalers-spacers-and-actuators"
    },
    {
      "title": "Dosage Form Drug Manufacturers cGMPs (10/93)",
      "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/dosage-form-drug-manufacturers-cgmps-1093"
    },
    {
      "title": "M9 Biopharmaceutics Classification System-Based Biowaivers",
      "url": "https://www.fda.gov/media/148472/download"
    },
    {
      "title": "Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/liposome-drug-products-chemistry-manufacturing-and-controls-human-pharmacokinetics-and"
    },
    {
      "title": "DOXIL (LIPOSOMAL) [DOXORUBICIN HYDROCHLORIDE] Label",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050718Orig1s060lbl.pdf"
    },
    {
      "title": "Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q6a-specifications-test-procedures-and-acceptance-criteria-new-drug-substances-and-new-drug-products"
    },
    {
      "title": "Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q7a-good-manufacturing-practice-guidance-active-pharmaceutical-ingredients"
    },
    {
      "title": "Using USP Reference Standards",
      "url": "https://www.usp.org/sites/default/files/usp/document/help/how_to_use_rs.pdf"
    },
    {
      "title": "Q2(R2) Validation of Analytical Procedures",
      "url": "https://www.fda.gov/media/161201/download"
    },
    {
      "title": "USP Reference Standards",
      "url": "https://www.usp.org/sites/default/files/usp/document/products-services/reference-standards-summary.pdf"
    },
    {
      "title": "Q1A(R2) Stability Testing of New Drug Substances and Products",
      "url": "https://www.fda.gov/media/71707/download"
    },
    {
      "title": "Container Closure Systems for Packaging Human Drugs and Biologics",
      "url": "https://www.fda.gov/media/70788/download"
    },
    {
      "title": "Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-and-closure-system-integrity-testing-lieu-sterility-testing-component-stability-protocol"
    },
    {
      "title": "Q8(R2): Pharmaceutical Development",
      "url": "https://database.ich.org/sites/default/files/Q8_R2_Guideline.pdf"
    },
    {
      "title": "SUPAC: Manufacturing Equipment Addendum",
      "url": "https://www.fda.gov/media/85681/download"
    },
    {
      "title": "Oral Solid Dosage Forms Pre/Post Approval Issues (1/94)",
      "url": "https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/oral-solid-dosage-forms-prepost-approval-issues-194"
    },
    {
      "title": "Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice",
      "url": "https://www.fda.gov/files/drugs/published/Sterile-Drug-Products-Produced-by-Aseptic-Processing-%E2%80%94-Current-Good-Manufacturing-Practice.pdf"
    },
    {
      "title": "Process Validation: General Principles and Practices",
      "url": "https://www.fda.gov/files/drugs/published/Process-Validation--General-Principles-and-Practices.pdf"
    },
    {
      "title": "Q10: Pharmaceutical Quality System",
      "url": "https://database.ich.org/sites/default/files/Q10_Guideline.pdf"
    },
    {
      "title": "Compounding and the FDA: Questions and Answers",
      "url": "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
    },
    {
      "title": "USP 〈797〉 FAQs, Updated December 11, 2023",
      "url": "https://pages.usp.org/rs/711-SXF-172/images/USP_HQS_797_FAQs_December2023_V6__002.pdf?version=0"
    },
    {
      "title": "Human Drug Compounding Laws",
      "url": "https://www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws"
    },
    {
      "title": "M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals",
      "url": "https://www.fda.gov/media/71542/download"
    },
    {
      "title": "Step 3: Clinical Research",
      "url": "https://www.fda.gov/patients/drug-development-process/step-3-clinical-research?lang=fr"
    },
    {
      "title": "Drug Development and Review Definitions",
      "url": "https://www.fda.gov/drugs/investigational-new-drug-application-ind/drug-development-and-review-definitions"
    },
    {
      "title": "The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective",
      "url": "https://www.fda.gov/drugs/information-consumers-and-patients-drugs/fdas-drug-review-process-ensuring-drugs-are-safe-and-effective?ftag=MSF0951a18"
    },
    {
      "title": "Statistical Principles for Clinical Development",
      "url": "https://www.fda.gov/media/175395/download"
    },
    {
      "title": "Surrogate Endpoint Resources for Drug and Biologic Development",
      "url": "https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development?trk=article-ssr-frontend-pulse_little-text-block"
    },
    {
      "title": "Step 4: FDA Drug Review",
      "url": "https://www.fda.gov/patients/drug-development-process/step-4-fda-drug-review?trk=article-ssr-frontend-pulse_little-text-block"
    },
    {
      "title": "Step 5: FDA Post-Market Drug Safety Monitoring",
      "url": "https://www.fda.gov/patients/drug-development-process/step-5-fda-post-market-drug-safety-monitoring"
    },
    {
      "title": "Postmarketing Requirements and Commitments: Introduction",
      "url": "https://www.fda.gov/drugs/guidance-compliance-regulatory-information/postmarket-requirements-and-commitments"
    },
    {
      "title": "Joint FIP/WHO Guidelines on Good Pharmacy Practice: Standards for Quality of Pharmacy Services",
      "url": "https://www.fip.org/files/fip/WHO/GPP%20guidelines%20FIP%20publication_final.pdf"
    },
    {
      "title": "Developing a rigorous clinical check procedure",
      "url": "https://inspections.pharmacyregulation.org/knowledge-hub/notable-practice/developing-a-rigorous-clinical-check-procedure-503"
    },
    {
      "title": "Registered pharmacy inspection report",
      "url": "https://inspections.pharmacyregulation.org/pharmacy/download/9011239-2024-06-13-22339.pdf"
    },
    {
      "title": "FDA Pharmacists Help You Use Medicines Safely",
      "url": "https://www.fda.gov/consumers/consumer-updates/fda-pharmacists-help-you-use-medicines-safely"
    },
    {
      "title": "Medicines: reclassify your product",
      "url": "https://www.gov.uk/guidance/medicines-reclassify-your-product"
    },
    {
      "title": "Rules for the sale, supply and administration of medicines for specific healthcare professionals",
      "url": "https://www.gov.uk/government/publications/rules-for-the-sale-supply-and-administration-of-medicines/rules-for-the-sale-supply-and-administration-of-medicines-for-specific-healthcare-professionals"
    },
    {
      "title": "Over-the-Counter (OTC) | Nonprescription Drugs | FDA",
      "url": "https://www.fda.gov/drugs/how-drugs-are-developed-and-approved/over-counter-otc-nonprescription-drugs"
    },
    {
      "title": "Update on the Pharmacy First service",
      "url": "https://www.england.nhs.uk/long-read/update-on-the-pharmacy-first-service/"
    },
    {
      "title": "Vaccinations — California State Board of Pharmacy",
      "url": "https://www.pharmacy.ca.gov/about/vaccinations.shtml"
    },
    {
      "title": "Revised FIP Basel Statements on the Future of Hospital Pharmacy",
      "url": "https://www.fip.org/files/fip/FIP_BASEL_STATEMENTS_ON_THE_FUTURE_OF_HOSPITAL_PHARMACY_2015.pdf"
    },
    {
      "title": "Basel Statements",
      "url": "https://www.fip.org/basel-statements"
    },
    {
      "title": "Radiopharmaceuticals: Production and Availability",
      "url": "https://www.iaea.org/sites/default/files/gc/gc51inf-3-att2_en.pdf"
    },
    {
      "title": "Operational Guidance on Hospital Radiopharmacy: A Safe and Effective Approach",
      "url": "https://www-pub.iaea.org/MTCD/Publications/PDF/Pub1342/Pub1342_web.pdf"
    },
    {
      "title": "ASHP Accreditation Standard for International Pharmacy Practice Residency Programs",
      "url": "https://www.ashp.org/-/media/assets/global/Docs/Advanced-IPPR-Accreditation-Standard---BOD-Approved.pdf"
    },
    {
      "title": "Opportunities and responsibilities in pharmaceutical care",
      "url": "https://pubmed.ncbi.nlm.nih.gov/2316538/"
    },
    {
      "title": "Developing Pharmacy Practice: A Focus on Patient Care",
      "url": "https://www.fip.org/files/fip/publications/DevelopingPharmacyPractice/DevelopingPharmacyPracticeEN.pdf"
    },
    {
      "title": "Medicines optimisation: Recommendations",
      "url": "https://www.nice.org.uk/guidance/ng5/chapter/Recommendations"
    },
    {
      "title": "Medicines optimisation: Overview",
      "url": "https://www.nice.org.uk/Guidance/NG5?print=true"
    },
    {
      "title": "Understanding CDER’s Postmarket Safety Surveillance Programs and Public Data",
      "url": "https://www.fda.gov/drugs/cder-conversations/understanding-cders-postmarket-safety-surveillance-programs-and-public-data"
    },
    {
      "title": "Guideline on good pharmacovigilance practices (GVP) Module VI – Management and reporting of adverse reactions to medicinal products (Rev 2)",
      "url": "https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-module-vi-management-and-reporting-adverse-reactions-medicinal-products-rev-2_en.pdf"
    },
    {
      "title": "Medication errors",
      "url": "https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/medication-errors"
    },
    {
      "title": "Product Problems",
      "url": "https://www.fda.gov/safety/reporting-serious-problems-fda/product-problems"
    },
    {
      "title": "Regulation and Prequalification: Pharmacovigilance",
      "url": "https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance"
    },
    {
      "title": "How to Report a Non-Emergency",
      "url": "https://www.fda.gov/safety/report-problem-fda/how-report-non-emergency"
    },
    {
      "title": "FDA Adverse Event Reporting System (FAERS) reporting and review",
      "url": "https://www.fda.gov/media/165667/download"
    },
    {
      "title": "FDA Adverse Event Monitoring System (AEMS) Public Dashboard",
      "url": "https://www.fda.gov/drugs/fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard"
    },
    {
      "title": "FDA's Sentinel Initiative - Background",
      "url": "https://www.fda.gov/safety/fdas-sentinel-initiative/fdas-sentinel-initiative-background"
    },
    {
      "title": "Focus Area: Product Safety Surveillance",
      "url": "https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-product-safety-surveillance"
    },
    {
      "title": "PDUFA VII Commitment: An Assessment of the Sentinel System (2022 to 2024)",
      "url": "https://www.fda.gov/industry/prescription-drug-user-fee-amendments/pdufa-vii-commitment-assessment-sentinel-system-2022-2024"
    },
    {
      "title": "Guideline on good pharmacovigilance practices: Module IX - Signal management",
      "url": "https://www.ema.europa.eu/system/files/documents/scientific-guideline/wc500123209_en.pdf"
    },
    {
      "title": "Guidance for PREP Act Coverage for Qualified Pharmacy Technicians and State-Authorized Pharmacy Interns for Childhood Vaccines, COVID-19 Vaccines, and COVID-19 Testing",
      "url": "https://www.hhs.gov/sites/default/files/prep-act-guidance.pdf"
    },
    {
      "title": "Core Elements of Outpatient Antibiotic Stewardship",
      "url": "https://www.cdc.gov/mmwr/volumes/65/rr/rr6506a1.htm"
    },
    {
      "title": "COVID-19: Guidelines for Pharmacists and the Pharmacy Workforce",
      "url": "https://www.fip.org/file/4729"
    },
    {
      "title": "Operational principles for good pharmaceutical procurement",
      "url": "https://iris.who.int/bitstream/handle/10665/66251/WHO_EDM_PAR_99.5.pdf"
    },
    {
      "title": "WHO model quality assurance system for procurement agencies",
      "url": "https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/trs986-annex3-who-model-quality-assurance-system-for-procurement-agencies.pdf"
    },
    {
      "title": "WHO Quality assurance policy for the procurement of essential medicines and other health products",
      "url": "https://www.who.int/publications/i/item/9789240023789"
    },
    {
      "title": "WHO work on supply systems",
      "url": "https://www.who.int/teams/health-product-policy-and-standards/medicines-selection-ip-and-affordability/medicines-policy/medicines-supply"
    },
    {
      "title": "Warehouse and Stock Management",
      "url": "https://emanual.who.int/p17new/s09/Pages/9-3-4-Warehouse-and-Stock-Management.aspx"
    },
    {
      "title": "Pillar 3 - Procurement, supply chain and inventory management",
      "url": "https://www.who.int/tools/quality-management-system-for-non-laboratory-settings/pillar-3--procurement-supply-chain-and-inventory-management"
    },
    {
      "title": "WHO good distribution practices for pharmaceutical products",
      "url": "https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/distribution/trs957-annex5-who-good-distribution-practices-for-pharmaceutical-products.pdf?sfvrsn=9c091cd5_2"
    },
    {
      "title": "TRS 1025 - Annex 7: Good storage and distribution practices for medical products",
      "url": "https://www.who.int/publications/m/item/trs-1025-annex-7"
    },
    {
      "title": "Storage and Handling of Immunobiologics",
      "url": "https://www.cdc.gov/vaccines/hcp/imz-best-practices/storage-handling-immunobiologics.html"
    },
    {
      "title": "Safeguarding Pharmaceutical Supply Chains in a Global Economy - 10/30/2019",
      "url": "https://www.fda.gov/news-events/congressional-testimony/safeguarding-pharmaceutical-supply-chains-global-economy-10302019"
    },
    {
      "title": "Report: Drug Shortages—Root Causes and Potential Solutions",
      "url": "https://www.fda.gov/drugs/drug-shortages/report-drug-shortages-root-causes-and-potential-solutions?trk=article-ssr-frontend-pulse_x-social-details_comments-action_comment-text"
    },
    {
      "title": "Product Identifiers Under the Drug Supply Chain Security Act",
      "url": "https://www.fda.gov/media/116304/download?attachment="
    },
    {
      "title": "What does FDA regulate?",
      "url": "https://www.fda.gov/about-fda/what-we-do/what-does-fda-regulate"
    },
    {
      "title": "Verify a License (License Search) - California State Board of Pharmacy",
      "url": "https://www.pharmacy.ca.gov/about/verify_lic.shtml"
    },
    {
      "title": "Pharmacy Inspections: Standards",
      "url": "https://inspections.pharmacyregulation.org/standards"
    },
    {
      "title": "Standards for pharmacy professionals",
      "url": "https://assets.pharmacyregulation.org/files/standards_for_pharmacy_professionals_may_2017_0.pdf?VersionId=C8dRrU1opDLdsuveSss5cKsPSwKObTi2"
    },
    {
      "title": "Pharmacist’s Manual, 2022 Edition",
      "url": "https://www.deadiversion.usdoj.gov/GDP/%28DEA-DC-046R1%29%28EO-DEA154R1%29_Pharmacist%27s_Manual_DEA.pdf"
    },
    {
      "title": "Diversion Control Division: Prescriptions Q&A",
      "url": "https://www.deadiversion.usdoj.gov/faq/prescriptions-faq.html"
    },
    {
      "title": "Code of Ethics for Pharmacists",
      "url": "https://www.pharmacist.com/Code-of-Ethics"
    },
    {
      "title": "Who We Are | AACP",
      "url": "https://www.aacp.org/article/who-we-are"
    },
    {
      "title": "Courses and qualifications for pharmacists | General Pharmaceutical Council",
      "url": "https://www.pharmacyregulation.org/students-and-trainees/pharmacist-education-and-training/courses-and-qualifications-pharmacists"
    },
    {
      "title": "Foundation training manual 2024/25",
      "url": "https://assets.pharmacyregulation.org/files/2024-06/GPhC-%20foundation-training-manual-2024-25.pdf"
    },
    {
      "title": "Graduate Degrees Defined | AACP",
      "url": "https://www.aacp.org/resource/graduate-degrees-defined"
    },
    {
      "title": "PharmD Program Accreditation | Accreditation Council for Pharmacy Education",
      "url": "https://www.acpe-accredit.org/program/pharmd-program-accreditation/"
    },
    {
      "title": "ACPE Standards 2025",
      "url": "https://www.acpe-accredit.org/wp-content/uploads/ACPEStandards2025.pdf"
    },
    {
      "title": "Revalidation framework",
      "url": "https://assets.pharmacyregulation.org/files/document/gphc_revalidation_framework_january_2018.pdf"
    },
    {
      "title": "Allows a Prescriber or a Pharmacy to Request a Patient’s Medication History",
      "url": "https://www.healthit.gov/isp/allows-a-prescriber-or-a-pharmacy-request-a-patients-medication-history?page=0"
    },
    {
      "title": "Clinical Decision Support",
      "url": "https://healthit.gov/clinical-quality-and-safety/clinical-decision-support"
    },
    {
      "title": "Clinical decision support (CDS)",
      "url": "https://healthit.gov/test-method/clinical-decision-support-cds/"
    },
    {
      "title": "Artificial Intelligence/Machine Learning: The New Frontier of Drug Development & Regulation",
      "url": "https://www.fda.gov/media/184265/download"
    },
    {
      "title": "FDA Proposes Framework to Advance Credibility of AI Models Used for Drug and Biological Product Submissions",
      "url": "https://www.fda.gov/news-events/press-announcements/fda-proposes-framework-advance-credibility-ai-models-used-drug-and-biological-product-submissions?trk=article-ssr-frontend-pulse_little-text-block"
    },
    {
      "title": "WHO issues first global report on Artificial Intelligence (AI) in health and six guiding principles for its design and use",
      "url": "https://www.who.int/news/item/28-06-2021-who-issues-first-global-report-on-ai-in-health-and-six-guiding-principles-for-its-design-and-use"
    },
    {
      "title": "FIP digital health in pharmacy education: Developing a digitally enabled pharmaceutical workforce",
      "url": "https://www.fip.org/file/4958"
    },
    {
      "title": "Guidance on wastewater and solid waste management for manufacturing of antibiotics",
      "url": "https://www.who.int/publications/i/item/9789240097254"
    },
    {
      "title": "Blog: Delivering high quality, low carbon respiratory care",
      "url": "https://www.england.nhs.uk/greenernhs/2023/02/blog-delivering-high-quality-low-carbon-respiratory-care/"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}